Clinical trials: Amyloid-beta
Alzheimer Disease
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
This research is designed to obtain efficacy and safety information for 123-I IMPY as an imaging biomarker for Alzheimer's disease (AD).
- Trial name
- NCT00287248
- Testing
- [123I] IMPY & SPECT Imaging
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease, Late Onset, Mild Cognitive Impairment
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
Dementia caused by Alzheimer's disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years.
- Conditions
- Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change
- Trial name
- ALPS (NCT05138848)
- Testing
- Time in Bed Restriction, Sleep Schedule
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Alzheimer Disease
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-308, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00544453
- Testing
- [123I] MNI-308
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Down Syndrome
Natural History of Amyloid Deposition in Adults With Down Syndrome
The primary objective of this study is to assess the presence of amyloid in non-demented/functionally stable adults with DS as a function of age, dividing the sample into amyloid-positive and amyloid-negative groups.
- Trial name
- NCT01303133
- Where
- 2 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Alzheimer's Disease
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The underlying goal of this study is to assess 123-I MNI-168 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of Alzheimer's Disease (AD) research participants and similarly aged and gender matched healthy…
- Trial name
- NCT00870519
- Testing
- I-123-MNI-168, 123-I MNI-168
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Dementia, Alzheimer Disease
Detecting Beta-amyloid in the Retina
Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths.
- Trial name
- NCT07529912
- Testing
- Hyperspectral camera
- Where
- Australia
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Alzheimer Disease
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV51, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in…
- Trial name
- NCT00556660
- Testing
- [123I] AV-151
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer's Disease
Implications of Amyloid Pathology
The purpose of this study is to determine whether asymptomatic older individuals with high amyloid burden will subsequently manifest cognitive impairment and eventually progress to clinical Alzheimer's Disease (AD).
- Trial name
- NCT00900770
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Elderly Individuals Aged 60 Years or Older, Mild Cognitive Impairment (MCI)
THE EFFECTS OF GAMBIR CATECHIN (UNCARIA GAMBIR ROXB) SUPPLEMENTATION ON COGNITIVE FUNCTION, EXPRESSION OF APP, MAPT, BDNF, IL-10, TGF-Β GENES, AND PLASMA MDA LEVELS IN THE ELDERLY.
Objective The primary objective of this clinical trial is to investigate the effects of gambir catechin administration on cognitive function, the expression of amyloid precursor protein (APP), microtubule-associated protein tau…
- Trial name
- NCT06604390
- Testing
- catechin extracts (health food), plasebo
- Where
- 2 sites in Fiji, Indonesia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Rahmi Novita Yusuf
Alzheimer Disease
A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
To test that LY450139, a gamma-secretase inhibitor, will reduce the rate of newly synthesize Amyloid Beta by determining the amount of newly synthesized 13C6 leucine-labeled Amyloid Beta in lumbar cerebrospinal fluid from…
- Trial name
- NCT00765115
- Testing
- LY450139
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Bioavailability, Gut Microbiome
Curcumin and Retinal Study
To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting…
- Conditions
- Bioavailability, Gut Microbiome, Safety
- Trial name
- NCT05774704
- Testing
- Low curcumin group, High curcumin group
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Alzheimer Disease
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-330, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00657813
- Testing
- MNI-330 as a brain SPECT tracer of Beta-Amyloid
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer's Disease, Healthy
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography…
- Trial name
- NCT00407576
- Testing
- [11C]MeS-IMPY
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Stress, Ageing
The Relaxation vs. Retreat Study
The purpose of this research study is to examine whether a short term meditation intervention can improve health, mood, and biological markers of cellular stress and aging in novice and experienced meditators compared to controls.
- Conditions
- Stress, Ageing, Wellbeing
- Trial name
- R&R (NCT01857830)
- Testing
- Meditation Retreat, Active Comparator Relaxation Group
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Memory Disorders, Alzheimer's Disease
Amyloid Plaque and Tangle Imaging in Aging and Dementia
Amyloid senile plaques (SPs) and neurofibrillary tangles (NFTs) are neuropathological hallmarks of Alzheimer's disease (AD) that also accumulate in key brain regions in association with normal aging.
- Trial name
- NCT00355498
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Postoperative Cognitive Dysfunction, Mild Cognitive Impairment
Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids
Postoperative cognitive dysfunction (POCD) can be a serious complication. The development of therapeutic strategies for the prevention and treatment of this condition requires the identification of subgroup of patients with the…
- Trial name
- NCT00850928
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Amyloid Beta Protein
Escitalopram Effects on CSF Amyloid Beta
Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures…
- Trial name
- NCT02161458
- Testing
- Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks
- Where
- 2 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Amyloid, Beta-Amyloid
Beta Amyloid PET/CT in Various Aβ-Related Disease
To evaluate the potential usefulness of 18F-92/AV45, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.
- Conditions
- Amyloid, Beta-Amyloid, Neurodegenerative Diseases
- Trial name
- NCT06725706
- Testing
- 18F-92/AV45, 11C-PIB
- Where
- 4 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University